Chemotherapy of vulvar cancer: a review

Deppe, Gunter; Mert, İsmail; Belotte, J; Winer, Ira

doi:10.1007/s00508-013-0338-y

Cited by 15 publications

(11 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In analogy to metastatic cervical cancer, the combination of carboplatin and paclitaxel has been increasingly used in recent years for the treatment of metastatic vulvar cancer because the combination is similarly effective and less toxic than the combination of cisplatin and paclitaxel. 26 Chemotherapy can be used in combination with concomitant radiation (chemoradiotherapy), either as a stand-alone treatment or as preoperative (neoadjuvant) treatment in patients with locally advanced disease. Various cytostatic drugs (cisplatin, 5-fluorouracil, mitomycin-C) are used in chemoradiotherapy to improve the local effect of radiation (chemosensitization).…”

Section: Systemic Treatmentmentioning

confidence: 99%

Modern treatment of vulvar cancer

Merlo

2020

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundVulvar cancer accounts for 3–5% of malignant diseases of the female genital tract. The Slovenian incidence rate is 5.5/100,000, which means 57 new cases per year. The most common histological type (90%) is squamous cell carcinoma. Based on etiology, it can be classified into the first type which correlates with human papillomavirus (HPV) infection and the second type which is not associated with HPV. The most common and long-lasting symptom of vulvar cancer is pruritus. The preferred diagnostic procedure to confirm the diagnosis is a punch or incision biopsy. Surgery in combination with radiotherapy is the standard treatment for vulvar cancer. Sentinel lymph node biopsy with lymphoscintigraphy is now a standard part of surgical treatment. Chemotherapy is a palliative treatment option.ConclusionsVulvar cancer is a rare disease. Because of the pathogenesis, surgery and radiotherapy are the main treatment modalities. The sentinel node biopsy (SNB) represents a contemporary approach to the vulvar cancer treatment and significantly reduces morbidity. Improvements in treatment of vulvar cancer contributed to the decrease of mortality among Slovenian women.

show abstract

Section: Systemic Treatmentmentioning

confidence: 99%

Modern treatment of vulvar cancer

Merlo

2020

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…The importance of a molecular approach in VSCC carcinogenesis is also demonstrated by Agostini et al (2016) [285], who revealed downregulation of the fragile histidine triad (FHIT) and upregulation of the high mobility group AT-hook 2 (HMGA2) gene via miR-30c and let-7a. The results of such translational research involving the molecular landscape of vulva cancer in the past was the basis for today's clinical target-directed therapeutic agents: for example, erlotinib, an inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR); bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VGFR); and pembrolizumab, an inhibitor of the programmed death-1 interaction with its ligand, called the PD1-PD-L1 immune checkpoint used in immunotherapy of VSCC [286][287][288][289].…”

Section: Advancements In Vc Therapy Based On Better Profiling and Novmentioning

confidence: 99%

Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology

Žúbor

Wang

Líšková

et al. 2020

IJMS

View full text Add to dashboard Cite

Vulvar cancer (VC) is a specific form of malignancy accounting for 5–6% of all gynaecologic malignancies. Although VC occurs most commonly in women after 60 years of age, disease incidence has risen progressively in premenopausal women in recent decades. VC demonstrates particular features requiring well-adapted therapeutic approaches to avoid potential treatment-related complications. Significant improvements in disease-free survival and overall survival rates for patients diagnosed with post-stage I disease have been achieved by implementing a combination therapy consisting of radical surgical resection, systemic chemotherapy and/or radiotherapy. Achieving local control remains challenging. However, mostly due to specific anatomical conditions, the need for comprehensive surgical reconstruction and frequent post-operative healing complications. Novel therapeutic tools better adapted to VC particularities are essential for improving individual outcomes. To this end, cold atmospheric plasma (CAP) treatment is a promising option for VC, and is particularly appropriate for the local treatment of dysplastic lesions, early intraepithelial cancer, and invasive tumours. In addition, CAP also helps reduce inflammatory complications and improve wound healing. The application of CAP may realise either directly or indirectly utilising nanoparticle technologies. CAP has demonstrated remarkable treatment benefits for several malignant conditions, and has created new medical fields, such as “plasma medicine” and “plasma oncology”. This article highlights the benefits of CAP for the treatment of VC, VC pre-stages, and postsurgical wound complications. There has not yet been a published report of CAP on vulvar cancer cells, and so this review summarises the progress made in gynaecological oncology and in other cancers, and promotes an important, understudied area for future research. The paradigm shift from reactive to predictive, preventive and personalised medical approaches in overall VC management is also considered.

show abstract

“…However, studies have already pointed to the characterization of vulvar cancer as chemosensitive, making chemotherapy a valid alternative for the management of these tumors; but data are still insufficient. [43,44]…”

Section: Radiotherapy/chemotherapymentioning

confidence: 99%

Cancer of the Vulva — A Review

Anschau¹,

Gonçalves²

2016

Gynecologic Cancers - Basic Sciences, Clinical and Therapeutic Perspectives

View full text Add to dashboard Cite

Cancer of the Vulva: a review In reporting on cancer of the vulva, we should keep in mind some important aspects of its epidemiology and its early detection. Most of the papers on the subject refer to vulvar cancer as a rare disease, accounting for 4 to 5% of all malignant neoplasms of the female genital tract and less than 1% of women's cancers. The incidence varies from 1 to 3.6 cases per 100,000 women, with peak incidence at ages 70-79 years. Even though the incidence increases with age, the proportion of young patients with vulvar cancer has greatly increased due to its association with infection with human papillomavirus (HPV). The risk of developing cancer of the vulva is related to behavioral, reproductive, hormonal and genetic aspects. Factors that increase risk include other genital cancers, chronic inflammatory diseases of the vulva, smoking, history of genital warts and vulvar intraepithelial neoplasia (VIN). We can consider that, given the epidemiological evidence, there are two etiologic pathways for vulvar cancer: one related to older patients, in the seventh or eighth decades of life, associated with mutations in TP53 and non-neoplastic epithelial disorders such as chronic inflammation or vulvar lichen, shows precursor lesions of differentiated VIN; the other is more common in young patients, accounts for approximately 43-60% of squamous carcinoma of the vulva, is associated with HPV infection, and is a common precursor lesion of VIN. Eighty-five to ninety percent of vulvar cancers are squamous in origin (squamous cell carcinoma); however, when considering the embryological origin of the vulva-the three germ layers-different histologic types can compose neoplasms affecting the region.

show abstract

Chemotherapy of vulvar cancer: a review

Cited by 15 publications

References 76 publications

Modern treatment of vulvar cancer

Modern treatment of vulvar cancer

Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology

Cancer of the Vulva — A Review

Contact Info

Product

Resources

About